Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein

被引:28
作者
Itagaki, Shirou [2 ]
Ochiai, Akiko [2 ]
Kobayashi, Masaki [2 ]
Sugawara, Mitsuru [1 ]
Hiran, Takeshi [2 ]
Iseki, Ken [2 ]
机构
[1] Hokkaido Univ Hosp, Dept Pharm, Kita Ku, Sapporo, Hokkaido 0608648, Japan
[2] Hokkaido Univ, Dept Biopharmaceut Sci & Pharm, Div Biopharmaceut Sci & Pharm,Kita Ku, Fac Pharmaceut Sci,Lab Clin Pharmaceut & Therapeu, Sapporo, Hokkaido 0600812, Japan
关键词
coenzyme; P-glycoprotein; intestine; Caco-2; transporter;
D O I
10.1021/jf800992p
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
In clinical trials, patients usually take many kinds of drugs at the same time. Thus, drug-drug interactions can often directly affect the therapeutic safety and efficacy of many drugs. Oral delivery is the most desirable means of drug administration. Changes in the activity of drug transporters may substantially influence the absorption of administered drugs from the intestine. However, there have been a few studies on food-drug interactions involving transporters. It is important to be aware of the potential of food-drug interactions and to act in order to prevent undesirable and harmful clinical consequences. Coenzyme Q10 (CoQ10) is very widely consumed by humans as a food supplement because of its recognition by the public as an important nutrient in supporting human health. Since intestinal efflux transporter P-glycoprotein (P-gp) is one of the major factors in drug-drug interactions, we focused on this transporter. We report here for the first time that CoQ10, which is widely used as a food supplement, affects the transport activity of P-gp.
引用
收藏
页码:6923 / 6927
页数:5
相关论文
共 29 条
[1]  
CATALIOTO RM, J PHARM SCI IN PRESS
[2]  
Elbling L, 1998, CYTOMETRY, V31, P187, DOI 10.1002/(SICI)1097-0320(19980301)31:3<187::AID-CYTO6>3.0.CO
[3]  
2-I
[4]   Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis [J].
Erkko, P ;
Granlund, H ;
Nuutinen, M ;
Reitamo, S .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (01) :82-88
[5]  
ERNSTER L, 1992, BIOFACTORS, V3, P241
[6]   INHIBITION OF LIPID-PEROXIDATION BY UBIQUINOL IN SUBMITOCHONDRIAL PARTICLES IN THE ABSENCE OF VITAMIN-E [J].
FORSMARK, P ;
ABERG, F ;
NORLING, B ;
NORDENBRAND, K ;
DALLNER, G ;
ERNSTER, L .
FEBS LETTERS, 1991, 285 (01) :39-43
[7]   Transepithelial transport of telmisartan in Caco-2 monolayers [J].
Goto, Y ;
Itagaki, S ;
Umeda, S ;
Kobayashi, M ;
Hirano, T ;
Iseki, K ;
Tadano, K .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (12) :2235-2239
[8]   COENZYME-Q10 - A NEW DRUG FOR CARDIOVASCULAR-DISEASE [J].
GREENBERG, S ;
FRISHMAN, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (07) :596-608
[9]   Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor [J].
Hauss, DJ ;
Fogal, SE ;
Ficorilli, JV ;
Price, CA ;
Roy, T ;
Jayara, AA ;
Keirns, JJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (02) :164-169
[10]  
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736